GlassScriptPhysician profile
Robert R Ajello
NPI 1518930916
$4,818.77
in general payments reported to CMS, 2019-2025
40 companies · $1,196 in 2025
The $1,196 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $10.96 · 2021: $379 · 2022: $1,081 · 2023: $1,074 · 2024: $1,077 · 2025: $1,196.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,347.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,347.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $681.58 | 2021-2025 | Repatha, Repatha |
| Janssen Pharmaceuticals, INC | $480.18 | 2021-2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $427.31 | 2021-2025 | Jardiance, Ofev, Jascayd |
| E.R. Squibb & Sons, L.L.C. | $407.50 | 2021-2025 | Eliquis, Camzyos |
| Harmony Biosciences LLC | $317.48 | 2022-2025 | Wakix |
| Alnylam Pharmaceuticals INC. | $269.69 | 2023-2025 | Onpattro, Amvuttra |
| Astrazeneca Pharmaceuticals LP | $265.94 | 2022-2025 | Wainua, Farxiga, Airsupra |
| Axsome Therapeutics, INC. | $199.49 | 2022-2025 | Sunosi |
| Merck Sharp & Dohme LLC | $187.28 | 2022-2025 | Verquvo, Belsomra |
| Pfizer INC. | $155.24 | 2021-2025 | |
| Glaxosmithkline, LLC. | $147.92 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Novo Nordisk INC | $147.41 | 2023-2025 | Wegovy, Ozempic |
| Kiniksa Pharmaceuticals, LTD. | $107.82 | 2021-2023 | Arcalyst |
| Scpharmaceuticals INC. | $104.89 | 2023-2025 | |
| Lexicon Pharmaceuticals, INC. | $88.98 | 2023-2024 | Inpefa |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Altathera Pharmaceuticals LLC | $61.77 | 2024-2025 | Sotalol Hydrochloride |
| Boston Scientific Corporation | $59.39 | 2022-2024 | Varithena Administration Pack |
| Cardiva Medical, INC. | $58.12 | 2024 | Optowire, Savvywire |
| Actelion Pharmaceuticals US, INC. | $52.78 | 2024-2025 | Opsumit, Uptravi |
| Regeneron Healthcare Solutions, INC. | $51.54 | 2022-2023 | Dupixent |
| Insmed, INC. | $47.54 | 2025 | Brinsupri, Arikayce |
| Abbott Laboratories | $43.99 | 2021-2025 | Cardiomems |
| United Therapeutics Corporation | $37.89 | 2024 | Tyvaso |
| Medicomp INC | $36.90 | 2024 | Telepatch Cardiac Monitor |
| Heartflow, INC. | $35.79 | 2024 | |
| Mallinckrodt Hospital Products INC. | $34.99 | 2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $33.24 | 2023-2025 | Lifevest |
| Verona Pharma, INC. | $31.02 | 2025 | Ohtuvayre |
| Lantheus Medical Imaging, INC. | $28.11 | 2023 | Definity |
| Edwards Lifesciences Corporation | $26.43 | 2025 | |
| Lilly USA, LLC | $26.30 | 2025 | Zepbound |
| Philips North America LLC | $25.59 | 2025 | Igt Devices Undivided |
| Mylan Specialty L.P. | $19.83 | 2024 | Yupelri |
| Tactile Systems Technology INC | $19.81 | 2025 | Flexitouch Plus, Nimbl |
| Avadel Cns Pharmaceuticals, LLC | $19.64 | 2023 | Lumryz |
| Impulse Dynamics (USA) INC. | $18.90 | 2023 | Optimizer |
| Amarin Pharma, INC. | $17.72 | 2021 | |
| Sanofi-Aventis U.S. LLC | $15.99 | 2022 | |
| Esperion Therapeutics, INC. | $13.65 | 2025 | Nexletol |
| Genzyme Corporation | $13.13 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Ajello listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.